Form 4: RA Capital Management Affiliates Report Director Equity Grants in Janux Therapeutics

RA Capital Management and its affiliated funds, along with key personnel, filed a Form 4 detailing the grant of restricted stock units and stock options to Dr. Jake Simson, a director of Janux Therapeutics, Inc., with beneficial ownership disclaimed by the reporting entities.

Summary

• RA Capital Management, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund II, L.P., Peter Kolchinsky, and Rajeev M. Shah filed a Form 4 regarding their beneficial ownership in Janux Therapeutics, Inc. (JANX).
• Dr. Jake Simson, a Partner of RA Capital Management and a director on Janux Therapeutics' board, was granted 3,750 Restricted Stock Units (RSUs) and stock options for 11,667 shares of common stock.
• The RSUs were granted at a price of $0 and represent a contingent right to receive one share of common stock each.
• The stock options have an exercise price of $25.46 per share.
• The 3,750 RSUs will vest on the earlier of June 11, 2026, or the date of the next annual meeting of Janux Therapeutics' stockholders, subject to Dr. Simson's continuous service.
• The 11,667 shares subject to the option will vest in equal monthly installments over 12 months following June 11, 2025, or fully vest on the date of the next annual meeting, subject to Dr. Simson's continuous service.
• RA Capital Management, L.P., its general partner, and the affiliated funds (RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fund II, L.P.), along with Dr. Kolchinsky and Mr. Shah, disclaim beneficial ownership of the reported RSUs and options, as Dr. Simson holds them for the benefit of the funds and is obligated to turn over any net proceeds.
• As of the transaction date, RA Capital Healthcare Fund, L.P. directly held 10,141,287 shares of Common Stock.
• As of the transaction date, RA Capital Nexus Fund II, L.P. directly held 1,048,406 shares of Common Stock.

Sentiment

Score: 5

Explanation: The document is a routine SEC Form 4 filing detailing insider transactions (equity grants to a director). It does not contain information that would significantly alter the company's financial outlook or operations, thus maintaining a neutral sentiment.

Positives

• The grant of equity compensation (RSUs and stock options) to a director aligns the director's interests with those of the shareholders, incentivizing long-term performance.
• The vesting schedules for both RSUs and stock options are tied to Dr. Simson's continuous service, promoting stability in board leadership.

Risks

• The issuance of new shares upon vesting and exercise of RSUs and options could lead to minor dilution for existing shareholders.
• The value of the equity compensation is dependent on the future stock price of Janux Therapeutics, Inc., which is subject to market fluctuations and company performance.

Future Outlook

The vesting schedules for the granted RSUs and stock options indicate an expectation of Dr. Jake Simson's continued service on the board of Janux Therapeutics, Inc. through at least the next annual meeting of stockholders or June 2026 for RSUs, and for 12 months following June 2025 for options.

Management Comments

• RA Capital Management, L.P., its general partner, and the affiliated funds (RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fund II, L.P.), along with Dr. Peter Kolchinsky and Mr. Rajeev Shah, disclaim beneficial ownership of any of the reported securities, except to the extent of their respective pecuniary interest therein.
• Dr. Jake Simson holds the option and RSU for the benefit of the Fund and the Nexus Fund II, and is obligated to turn over to the Adviser any net cash or stock received upon exercise or settlement, which will offset advisory fees owed by the Fund and the Nexus Fund II to the Adviser.

Industry Context

The grant of equity compensation to directors is a common practice in the biotechnology and pharmaceutical industries, including for companies like Janux Therapeutics, Inc., to attract and retain experienced board members and align their interests with long-term company performance. This Form 4 filing is a routine disclosure of such compensation.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) and stock options to a director is a standard form of equity compensation in the biotech sector, comparable to practices at companies like Moderna, Inc. or BioNTech SE, which frequently use equity to incentivize leadership.
• The vesting schedules (over 12 months for options, or until the next annual meeting/one year for RSUs) are typical for director compensation, aiming to retain talent and align interests over a reasonable period, similar to vesting schedules seen at companies such as Gilead Sciences, Inc. or Amgen Inc. for their non-employee directors.
• The disclaimer of beneficial ownership by the investment manager and funds for equity held by a partner serving as a director, where proceeds are remitted to the funds, is a specific arrangement common among venture capital or investment firms whose partners sit on portfolio company boards, ensuring the benefit accrues to the funds' limited partners rather than the individual director personally.

Related Party Transactions

• The grant of Restricted Stock Units and stock options to Dr. Jake Simson, a director of Janux Therapeutics and a Partner at RA Capital Management (a significant shareholder), constitutes a related party transaction.
• Dr. Simson's arrangement to hold the option and RSU for the benefit of RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fund II, L.P., and to turn over net cash or stock received to RA Capital Management to offset advisory fees, is a related party arrangement.

Stakeholder Impact

• Shareholders: Minor potential for dilution from the issuance of new shares upon vesting and exercise of the granted equity, but also potential for increased alignment of director interests with shareholder value.
• Employees: No direct impact mentioned, but standard equity compensation practices can contribute to a competitive compensation framework.

Next Steps

• Vesting of the 3,750 Restricted Stock Units on the earlier of June 11, 2026, or the date of the next annual meeting of stockholders.
• Vesting of the 11,667 shares subject to stock options in equal monthly installments over 12 months following June 11, 2025, or fully vested on the date of the next annual meeting.
• Potential exercise of the stock options by Dr. Jake Simson, with proceeds to be turned over to RA Capital Management for the benefit of the affiliated funds.

Key Dates

Keywords

SEC Form 4, Janux Therapeutics, RA Capital Management, Insider Transaction, Beneficial Ownership, Restricted Stock Units, Stock Options, Equity Compensation, Director Compensation, JANX